Every participant in a new bowel cancer immunotherapy trial remained cancer-free nearly three years after receiving pembrolizumab before surgery.
Original Source:
https://www.foxnews.com/health/patients-remain-cancer-free-nearly-3-years-receiving-experimental-immunotherapy
